MT-ND1 — Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 1

The MT-ND1 gene is located in your mitochondrial DNA, which is inherited exclusively from your mother. It provides the instructions for making a protein called NADH dehydrogenase 1. This protein is a crucial part of a large machine in your cells called complex I, which acts like a power plant. It helps convert the food you eat into ATP, the main energy source that your cells need to function properly, especially in energy-hungry organs like the brain, muscles, and eyes. When there is a mutation in the MT-ND1 gene, the complex I power plant cannot work efficiently. This leads to a decrease in energy production and an increase in harmful molecules called reactive oxygen species, which can damage cells. Because the optic nerve and brain require a lot of energy, they are particularly vulnerable to these energy shortages. As a result, mutations in this gene can lead to conditions like Leber hereditary optic neuropathy (LHON), which causes sudden vision loss, or other neurological disorders like MELAS and Leigh syndrome. These conditions affect how the brain and muscles work, leading to symptoms such as muscle weakness, stroke-like episodes, and movement problems.

Gene description: The MT-ND1 gene provides instructions for making the NADH dehydrogenase 1 protein, which is a core subunit of the mitochondrial respiratory chain complex I. This large enzyme complex is located in the inner mitochondrial membrane and is essential for oxidative phosphorylation, the process that converts energy from food into ATP. Mutations in the MT-ND1 gene disrupt cellular energy production and are primarily associated with mitochondrial diseases affecting the nervous system and vision.

Patient and family guide: The MT-ND1 gene is located in your mitochondrial DNA, which is inherited exclusively from your mother. It provides the instructions for making a protein called NADH dehydrogenase 1. This protein is a crucial part of a large machine in your cells called complex I, which acts like a power plant. It helps convert the food you eat into ATP, the main energy source that your cells need to function properly, especially in energy-hungry organs like the brain, muscles, and eyes. When there is a mutation in the MT-ND1 gene, the complex I power plant cannot work efficiently. This leads to a decrease in energy production and an increase in harmful molecules called reactive oxygen species, which can damage cells. Because the optic nerve and brain require a lot of energy, they are particularly vulnerable to these energy shortages. As a result, mutations in this gene can lead to conditions like Leber hereditary optic neuropathy (LHON), which causes sudden vision loss, or other neurological disorders like MELAS and Leigh syndrome. These conditions affect how the brain and muscles work, leading to symptoms such as muscle weakness, stroke-like episodes, and movement problems.

Gene function: The MT-ND1 gene encodes the NADH dehydrogenase 1 protein, a highly hydrophobic core subunit of mitochondrial complex I. It plays a critical role in the assembly and catalytic activity of the complex. The protein is essential for the initial step of the electron transport chain, facilitating the transfer of electrons from NADH to ubiquinone (coenzyme Q10). This electron transfer is coupled with the translocation of protons across the inner mitochondrial membrane, generating the electrochemical gradient required for ATP synthesis.

Protein structure: The MT-ND1 protein is a 36 kDa polypeptide composed of 318 amino acids. It is a highly hydrophobic transmembrane protein that forms part of the core of the hydrophobic protein fragment of complex I. The structure is characterized by multiple transmembrane helices that anchor the complex within the inner mitochondrial membrane. It interacts with other mitochondrially encoded subunits to form the membrane arm of complex I, which is essential for proton pumping and ubiquinone binding.

Molecular function: At the molecular level, the MT-ND1 protein functions as a core subunit of the NADH-ubiquinone oxidoreductase (complex I), the largest enzyme of the mitochondrial electron transport chain. Its primary molecular function is to participate in the transfer of electrons from NADH to ubiquinone (coenzyme Q10). MT-ND1 is believed to be directly involved in the formation of the ubiquinone-binding site, as it binds rotenone and its analogs, which are known inhibitors that interact with the ubiquinone binding pocket. The transfer of electrons through complex I is coupled to the pumping of four protons from the mitochondrial matrix into the intermembrane space. This proton translocation creates an electrochemical gradient across the inner mitochondrial membrane, which is subsequently utilized by ATP synthase to drive the production of ATP, the primary energy currency of the cell.

Mutation spectrum: The mutation spectrum of the MT-ND1 gene primarily consists of homoplasmic or heteroplasmic point mutations, particularly missense mutations that alter highly conserved amino acids. The most common mutation is the 3460G>A transition, which replaces alanine with threonine (A52T) and accounts for about 13% of Leber hereditary optic neuropathy (LHON) cases. Other significant missense mutations include 4160T>C (L285P) and 3928G>C (V208L). In addition to missense variants, some nonsense mutations and small deletions have been reported in severe mitochondrial disorders like MELAS and Leigh syndrome. These mutations typically disrupt the structural integrity of complex I, impairing its assembly, stability, or catalytic efficiency, thereby leading to mitochondrial dysfunction.

Clinical significance: Mutations in the MT-ND1 gene are clinically significant as they cause severe mitochondrial diseases by impairing oxidative phosphorylation and cellular energy production. The most prominent condition is Leber hereditary optic neuropathy (LHON), characterized by subacute, painless bilateral vision loss due to the degeneration of retinal ganglion cells and the optic nerve. The 3460G>A mutation is a primary cause of LHON. Additionally, MT-ND1 mutations are associated with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS), leading to seizures, muscle weakness, and cognitive impairment. Other associated conditions include Leigh syndrome, a severe early-onset neurodegenerative disorder, and isolated mitochondrial complex I deficiency. The clinical severity often depends on the level of heteroplasmy (the proportion of mutated mitochondrial DNA) and the specific tissue's energy demands, with the central nervous system and eyes being the most susceptible.

Inheritance: Mitochondrial

Chromosomal location: Mitochondrial (MT: 3,307-4,262)

Research and therapeutic approaches: Therapeutic approaches for MT-ND1-related disorders are currently focused on symptom management, metabolic support, and emerging gene therapies. Traditional treatments include antioxidant supplements like idebenone (a synthetic analog of coenzyme Q10), which can bypass complex I defects and improve electron transfer, showing some efficacy in recovering vision in LHON patients. Recently, adeno-associated virus (AAV)-mediated gene therapy has shown significant promise. Specifically, rAAV2-ND1 gene therapy has been developed to deliver a functional copy of the ND1 gene directly into the eye via intravitreal injection. Preliminary clinical trials have demonstrated that this approach is safe and can effectively restore mitochondrial function, protect retinal ganglion cells, and improve visual acuity in patients with LHON caused by MT-ND1 mutations. Mitochondrial replacement therapy is also being explored to prevent the maternal transmission of these mutations.